Navigation Links
Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)
Date:12/8/2008

to treatment or returns within six months of completing such treatment

Bulky tumors - when individual tumor masses are >5cm in diameter

Salvage therapy - a final treatment for people who are non-responsive to or cannot tolerate other available therapies for a particular condition and whose prognosis is often poor

Arzerra(TM) is the proposed registered trademark to be used in the United States and Europe.

To access the latest GSK Oncology media materials, visit www.gskcancermedia.com

    GSK Enquiries:
    Onsite Media
    enquiries:             Greg Clarke - non US media only   +1 610 405 0053
                           Ken Inchausti - US media only     +1 267 809 7552

    UK Media enquiries:    Philip Thomson                   +44 20 8047 5502
                           Claire Brough                    +44 20 8047 5502
                           Alice Hunt                       +44 20 8047 5502
                           Gwenan White                     +44 20 8047 5502

    US Media enquiries:    Nancy Pekarek                     +1 215 751 7709
                           Mary Anne Rhyne                   +1 919 483 2839
                           Sarah Alspach                     +1 215 751 7709

    European Analyst
    /Investor enquiries:   David Mawdsley                   +44 20 8047 5564
                           Sally Ferguson                   +44 20 8047 5543
                           Gary Davies                      +44 20 8047 5503
    US Analyst/ Investor
     enquiries:            Jen Hill                          +1 215 751 7002
                           Tom Curry                         +1 215 751 5419

    Genmab enquiries:      Helle Husted, Sr. Director, Investor Relations
                           T: +45 33 44 77 30;
                           M: +45 25 27 47
'/>"/>
SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
5. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
8. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
9. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
10. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
11. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015  CytoSorbents Corporation (NASDAQ CM: CTSO), ... extracorporeal cytokine adsorber to reduce deadly inflammation in ... of $385,642, net of transaction costs, in non-dilutive ... Business Tax Certificate Transfer Program sponsored by the ...
(Date:1/23/2015)... CHENGDU, China , Jan. 23, 2015 Tianyin ... pharmaceutical company that specializes in the development and sale ... branded generics and active pharmaceutical ingredients (API) today announced ... Facility (JCM) API operation. 1. Following the ...
(Date:1/22/2015)... Jan. 22, 2015  ResMed Inc. (NYSE: RMD ) ... Revenue for the quarter was $423.0 million, a 10 percent ... 14 percent increase on a constant currency basis). Net income ... the quarter ended December 31, 2013. Diluted earnings per share ...
Breaking Medicine Technology:CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11
... Over 200 organizations, community leaders, health care professionals, ... across the country today urged Express Scripts to ... and allow the nation,s largest pharmacy chain to return ... stopped providing in-network coverage for prescriptions filled at Walgreens ...
... SUNNYVALE, Calif., Jan. 17, 2012   Accuray Incorporated ... company, announced today that CHRISTUS MUGUERZA Hospital Alta Especialidad ... CyberKnife® Robotic Radiosurgery System . CHRISTUS MUGUERZA is ... benefits of the CyberKnife System to treat tumors anywhere ...
Cached Medicine Technology:Over 200 Community Leaders and Organizations Across the Nation Urge Express Scripts To Reach Agreement With Walgreens 2First CyberKnife Robotic Radiosurgery System Goes Live in Mexico 2First CyberKnife Robotic Radiosurgery System Goes Live in Mexico 3First CyberKnife Robotic Radiosurgery System Goes Live in Mexico 4
(Date:1/22/2015)... the premier women’s dress supplier, has recently released its ... of AngelWeddingDress.com to find more details. , Many ... a bridal party. AngelWeddingDress offers a variety of gorgeous ... wedding dresses are specially designed for 2015. , AngelWeddingDress ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Autocarinsurancebest.com has released ... purchasing a commercial auto insurance policy . , Auto ... their vehicles. It is no longer necessary to call an ... are now available online on a single website: http://autocarinsurancebest.com/ ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Yesterday, ... Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were honored ... leadership in advancing biotechnology, biomedical science, medical device ... Olsen each received the “2014 Life Sciences Champion” ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and ... relationship in an effort to further promote visibility and adoption ... has long made AMA journals available via its subscription services, ... JAMA Network. , Long known as both a ...
(Date:1/22/2015)... Richmond, VA (PRWEB) January 22, 2015 ... the power at the Science Museum of Virginia. Wicked ... 24. , Wicked Plants unearths 75 poisonous, carnivorous and ... traverse through each room to uncover the biochemical, physical ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... The New Year is here, but are ... pounds in a healthy way that,ll,last past ... GlaxoSmithKline at:, http://media.medialink.com/WebNR.aspx?story=34274 , Registered journalists ... for free and unrestricted use at ...
... Biosciences,Inc. (Nasdaq: RDEA ) today announced that ... the United Kingdom has authorized a,Phase 2a clinical ... (NNRTI), in patients with human immunodeficiency,virus (HIV), the ... clear unmet need for new NNRTIs that have ...
... The board of trustees of,the Pan American Health ... executive director. He comes to the foundation with 30 ... He,follows Ms. Jess Gersky who is retiring at the ... served as the mission director in Mexico for,the US ...
... Cancer Center in Philadelphia have found that a signaling ... is turned on in nearly all recurrent prostate cancers ... hold up, the protein, called Stat5, may be a ... In addition, the researchers, led by Marja Nevalainen, M.D., ...
... happen to kids if precautions are skipped, experts say ... provide kids with great exercise and fun, but proper ... trauma experts. , "We see a startling number of ... and beyond," Amy Teddy, manager of the pediatric injury ...
... 28 Grubb & Ellis,Healthcare REIT, Inc. has acquired ... on December 21, 2007., Park Place Office Park ... square feet on eight and a half,acres in Dayton, ... in 1987,1988, and 2002, respectively, and offer tenants a ...
Cached Medicine News:Health News:Ardea Biosciences' Lead NNRTI for HIV, RDEA806, to Enter Phase 2a Proof-of- Concept Clinical Trial 2Health News:Ardea Biosciences' Lead NNRTI for HIV, RDEA806, to Enter Phase 2a Proof-of- Concept Clinical Trial 3Health News:International Development Expert to Lead the Pan American Health and Education Foundation 2Health News:Jefferson scientists find protein potential drug target for treatment-resistant prostate cancer 2Health News:Put Safety First During Winter Fun 2Health News:Grubb & Ellis Healthcare REIT Acquires Park Place Office Park in Dayton, Ohio 2Health News:Grubb & Ellis Healthcare REIT Acquires Park Place Office Park in Dayton, Ohio 3
Soft Non-Latex, Adjustable Flange Nasopharyngeal Airway. Pediatric sizes available. Non-Latex Mediprene material with soft elastic finish. Adjustable flange for a better fit and increased patient com...
Soft Guedel Oral Airways...
All oral and nasal airways are manufactured with smooth, rounded edges for increased patient comfort and safety., ,Portex® offers a broad selection of airways for a variety of clinical applicati...
... Rapid intubation of difficult airways., ... time and accuracy are critical. Now you ... effective ventilation with the Combitube®: Esophageal/Tracheal double-Lumen ... the Combitube airway is designed to establish ...
Medicine Products: